| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e70c0aeade92d7571d955d3b90ea06e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56988 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate |
1990-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d77d5705f7d755aa2323d2bfe44d8f76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19d9151046d653d8389b7ccc3e363847 |
| publicationDate |
1990-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9008959-A1 |
| titleOfInvention |
HIV p17 ASSAYS FOR MONITORING DEVELOPMENT OF AIDS |
| abstract |
Disease state of individuals who are seropositive for antibodies to HIV can be monitored and predicted by intermittently determining the level of HIV p17 and/or free complexing anti-p17 antibody in a body fluid. Levels of HIV p24 and free complexing anti-p24 can be simultaneously determined for information of maximum prognostic significance. Level of p17 can be measured by means of a heterogeneous sandwich ELISA. Level of anti-p17 antibody can be measured by means of a binding capacity assay using the same ELISA and exogenous p17. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5391479-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2666657-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9410570-A1 |
| priorityDate |
1989-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |